Ceftizoxime
Appearance
This articleneeds additional citations forverification.(April 2013) |
![]() | |
Clinical data | |
---|---|
Trade names | Cefizox |
AHFS/Drugs | Consumer Drug Information |
MedlinePlus | a684043 |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChemCID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard(EPA) | |
ECHA InfoCard | 100.210.846 |
Chemical and physical data | |
Formula | C13H13N5O5S2 |
Molar mass | 383.40g·mol−1 |
Ceftizoximeis a third-generationcephalosporinavailable forparenteral administration.[1] Unlike other third-generation cephalosporins, the whole C-3 side chain in ceftizoxime has been removed to preventdeactivationbyhydrolytic enzymes. It rather resemblescefotaximein its properties, but is not subject tometabolism.It was removed from the US Market in 2007.
Synthesis
[edit]Injectable third generation cephalosporin antibiotic related tocefotaxime,q.v.Exhibits broad spectrum activity and resistance to β-lactamase hydrolysis.
![](https://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Ceftizoxime_synthesis.svg/500px-Ceftizoxime_synthesis.svg.png)
References
[edit]- ^Aldridge KE (1990). "An update on the in vitro activity of ceftizoxime and other cephalosporin/cephamycin antimicrobial agents against clinically significant anaerobic bacteria".Clinical Therapeutics.12 Suppl C: 3–12.PMID2202509.
- ^DE 2810922,Takaya T, Hisashi T, Kiyoshi T, Toshiyuki C, "New cepham compounds and processes for the production thereof", issued 29 August 1985, assigned toFujisawa
- ^US 4427674,Takaya T, Hisashi T, Kiyoshi T, Toshiyuki C, "Cephem compounds", issued 24 January 1984, assigned toFujisawa